https://www.selleckchem.com/products/lyn-1604.html
PURPOSE The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact of BM subtype, as well as distinct biological features of those subtypes, on response to BRAF/MEK/EGFR inhibition in patients with CRC. EXPERIMENTAL DESIGN Paired fresh tumour biopsies were acquired at baseline and on day 15 of treatment from
Like
Comment
Share
